向“领跑者”跨越! 中国双抗药物再迎高光时刻

每日经济新闻
Jan 14

2026年1月12日,第四十四届摩根大通医疗健康大会在美国旧金山召开,当全球生物医药界的目光聚焦于该会议时,大洋彼岸的中国接连传来重磅消息。  荣昌生物(SH688331,股价103.34元,市值582.54亿元)率先宣布与全球制药巨头——艾伯维集团控股公司(以下简称艾伯维)达成56亿美元授权协议,其PD-1/VEGF双抗——RC148成功“出海”;几乎在同一时间,康方生物(HK09926,股价...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10